Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03820414
Recruitment Status : Completed
First Posted : January 29, 2019
Last Update Posted : February 11, 2021
Sponsor:
Collaborators:
IDRI
Mogam Biotechnology Research Institute
Green Cross Corporation
Information provided by (Responsible Party):
Curevo Inc

Tracking Information
First Submitted Date  ICMJE January 24, 2019
First Posted Date  ICMJE January 29, 2019
Last Update Posted Date February 11, 2021
Actual Study Start Date  ICMJE January 3, 2019
Actual Primary Completion Date April 4, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 25, 2019)
  • The number of subjects experiencing solicited local injection site reactions within 7 days following each study injection. [ Time Frame: 7 Days ]
  • The number of subjects experiencing solicited systemic reactions within 7 days following each study injection. [ Time Frame: 7 Days ]
  • The number of subjects spontaneously reporting unsolicited adverse events from Day 0 through 28 days after the last injection. [ Time Frame: 28 Days ]
  • The number of medically-attended adverse events considered related to any of the study injections reported at any point during the study period events and potential immune-mediated medical conditions considered related to any of the study injections [ Time Frame: 421 Days ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 25, 2019)
  • The frequencies of vaccine protein-specific T cells elicited by the CRV101 study vaccine at specified time points. [ Time Frame: Day 0, 7, 28, 56, 63, 84, 196, and 365 ]
  • The levels of vaccine protein-specific antibodies elicited by the CRV101 study vaccine at specified time points [ Time Frame: Day 0, 7, 28, 56, 63, 84, 196, and 365 ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
Official Title  ICMJE A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Antigen Dose-Escalation and Adjuvant Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
Brief Summary The purpose of this clinical trial is to evaluate the safety, tolerability, and immunogenicity of vaccine candidate CRV-101, investigational vaccine in healthy adult subjects in the United States.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE
  • Herpes Zoster
  • Varicella Zoster
Intervention  ICMJE
  • Biological: CRV 101
    (Different formulations)
  • Biological: Placebo
    2 doses administered IM in deltoid region of non-dominant arm
    Other Name: Saline injection
Study Arms  ICMJE
  • Experimental: CRV101 Group 1
    Subjects receive 2 doses of the candidate CRV-101 formulation 1, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
    Intervention: Biological: CRV 101
  • Experimental: CRV 101 Group 2
    Subjects receive 2 doses of the candidate CRV-101 formulation 2, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
    Intervention: Biological: CRV 101
  • Experimental: CRV 101 Group 3
    Subjects receive 2 doses of the candidate CRV-101 formulation 3, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
    Intervention: Biological: CRV 101
  • Experimental: CRV 101 Group 4
    Subjects receive 2 doses of the candidate CRV-101 formulation 4, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
    Intervention: Biological: CRV 101
  • Placebo Comparator: Control Group
    Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
    Intervention: Biological: Placebo
Publications * Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013 Jul 18;369(3):255-63. doi: 10.1056/NEJMcp1302674. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 25, 2019)
90
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE April 30, 2020
Actual Primary Completion Date April 4, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Males and non-pregnant females ≥ 18 to < 50 years of age at the time of enrollment.
  2. In good general health as confirmed by a medical history and physical exam, vital signs*, and screening laboratories conducted no more than 30 days prior to study injection administration.

    *Oral Temperature <38°C, respiratory rate < 17 breaths pm, heart rate ≤100 bpm and >54 bpm, systolic blood pressure ≤150 mmHg and >89 mmHg, diastolic blood pressure ≤95 mmHg.

    NOTE: Athletically trained subjects with a heart rate ≥40 may be enrolled at the discretion of the principal investigator or designated licensed clinical investigator and reasoning must be documented.

  3. Screening laboratory values must be within normal range or not clinically significant as determined by the PI and approved by the Medical Monitor: sodium, potassium, BUN, ALT, AST, total bilirubin, alkaline phosphatase, creatinine, random glucose, WBC with differential, hemoglobin, and platelet count.
  4. Negative HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody.
  5. Normal urinalysis or if abnormal determined to be not clinically significant by the PI and the Medical Monitor (trace protein is acceptable without medical monitor approval).
  6. Urine test result for recreational drugs/drugs of abuse that in the opinion of the PI would not be a concern for subject's safety, or ability to reliably attend visits, and perform required protocol procedures. If urine drug test is positive, reasoning for inclusion must be documented.
  7. Females of childbearing potential* must have a negative serum pregnancy test at screening and a negative urine pregnancy test on the day of each study vaccination (prior to vaccination), must not be breast-feeding, and women in sexual relationships with men must agree to practice acceptable contraception** for the 30-day period before Day 0 through 90 days after the last study injection. These precautions are necessary due to unknown effects that CRV-101 might cause in a fetus or newborn infant.

    *Not sterilized via tubal ligation, bilateral oophorectomy, hysterectomy or successful Essure® placement (permanent, non-surgical, non-hormonal sterilization) with documented radiological confirmation test at least 90 days after the procedure, and still menstruating or < 1 year of the last menses if menopausal). Post-menopausal defined as at least 12 months spontaneous amenorrhea and confirmed with FSH > 40 mIU/ml.

    **Includes, but is not limited to, sexual abstinence, monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to the subject receiving study product, barrier methods such as condoms or diaphragms with spermicide or foam, effective intrauterine devices, NuvaRing ®, and licensed hormonal methods such as implants, injectables or oral contraceptives ("the pill").

  8. Exposure to VZV as documented by one of the following: subject reported clinical history of chickenpox, previous vaccination against VZV with Varivax® (or other low-titer live-attenuated varicella vaccine), or positive serology test for VZV.
  9. Must be able to understand informed consent in English and capable of completing a study diary card in English.
  10. Must provide informed consent prior to any screening procedures performed, be able and willing to make all study visits, be reachable by telephone or personal contact by the study site personnel, and have a permanent address.
  11. Willing to abstain from donating whole blood or blood derivatives until after Day 365 visit.

Exclusion Criteria:

  1. History of chickenpox or herpes zoster in the past 3 years.
  2. Immunization with a vaccine against herpes zoster (Zostavax® or Shingrix®).
  3. Participation in another experimental protocol with last receipt of any device, vaccine, or other immunomodulator investigational products within the past 180 days of enrollment, or last receipt of non-device, non-vaccine, non-immunomodulator investigational products with in the last 90 days of enrollment or 5 half-lives whichever is greater, or planned participation in any other investigational study during the study period.
  4. Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs (e.g. oral or injected steroids, such as prednisone; high dose inhaled steroids; biologics (e.g. TNF inhibitor, or other cytokine inhibitors) or cytotoxic therapies, such as chemotherapy drugs or radiation) within 180 days prior to enrollment and during the study through Day 365 visit. For corticosteroids, this will mean prednisone ≥ 0.5 mg/kg/day, or equivalent. Low dose inhaled and topical steroids are allowed.
  5. Received a blood transfusion or immunoglobulin within past 90 days of enrollment.
  6. Donated blood products (platelets, whole blood, plasma, etc.) within past 60 days of enrollment.
  7. Received any vaccine within past 30 days prior to enrollment and no planned immunizations while on study with the exception of seasonal influenza vaccine which must not be given until 30 days after the last study injection and the Day 84 immunology blood has been drawn and a 30 day window prior to each immunology blood draw (Day 196, 365).
  8. History of autoimmune disease or other causes of immunosuppressive states.
  9. History of any acute or chronic illness (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic or renal disorders, controlled hypertension), or use of medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.
  10. Rash, tattoos, or any other dermatological condition that could adversely affect the vaccine injection site or interfere with its evaluation.
  11. BMI that poses a health risk in the opinion of the Principal Investigator.
  12. Hypertension (systolic >150 or diastolic >95).
  13. History of significant psychiatric illness (including past history of suicidal ideation or attempt) with or without current use of medication.
  14. Known or suspected alcohol or drug abuse within the past 5 years.
  15. Chronic smoker (> 20 pack years).
  16. Subjects with a history of previous anaphylaxis or severe allergic reaction to vaccines or unknown allergens.
  17. Subjects who are unlikely to cooperate with the requirements of the study protocol or who are likely to be unreliable in attending study visits or other reason that the Principal Investigator determines that the subject will not be a good candidate to participate in this study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 49 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03820414
Other Study ID Numbers  ICMJE CRV-101-100
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Curevo Inc
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Curevo Inc
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE
  • IDRI
  • Mogam Biotechnology Research Institute
  • Green Cross Corporation
Investigators  ICMJE
Principal Investigator: John E Ervin, MD The Center for Pharmaceutical Research
Study Director: Corey Casper, MD IDRI
Study Chair: Lisa Shelton Curevo Inc
PRS Account Curevo Inc
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP